Bacteria mediated tumor therapy recent advances challenges and future perspectives

Area of Science:

• Microbiology
• Oncology
• Biotechnology

Background:

• Bacteria can lyse tumor cells and modulate the tumor microenvironment.
• Anaerobic bacteria preferentially colonize hypoxic tumors, acting as in situ therapeutic agents.
• Engineered bacteria and biohybrid systems offer precision tumor therapy via synthetic biology.

Purpose of the Study:

• To review the development and mechanisms of bacteria-mediated tumor therapy.
• To discuss engineered bacteria and biohybrid systems for precision cancer treatment.
• To identify challenges and propose strategies for clinical translation of bacteria-based therapies.

Main Methods:

• Systematic review of historical development and anti-tumor mechanisms.
• Analysis of genetic engineering strategies and multimodal biohybrid systems.
• Discussion of advantages, limitations, and comparative characteristics of different platforms.

Main Results:

• Bacteria-derived therapies demonstrate potential for targeted drug delivery and immune activation.
• Engineered bacteria can be programmed for specific therapeutic functions.
• Significant hurdles remain, including biosafety, off-target effects, and regulatory guidelines.

Conclusions:

• Bacteria-mediated tumor therapy holds great promise but requires further development for clinical application.
• Advancements in synthetic biology are crucial for creating controllable and effective bacteria-based treatments.
• Addressing safety and regulatory concerns is essential for successful translation to patient care.